Cover Image
市場調查報告書

疫苗的全球市場 至2022年的預測:各技術、疾病、給藥途徑、終端用戶、類型

Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022

出版商 MarketsandMarkets 商品編碼 278597
出版日期 內容資訊 英文 206 Pages
訂單完成後即時交付
價格
Back to Top
疫苗的全球市場 至2022年的預測:各技術、疾病、給藥途徑、終端用戶、類型 Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022
出版日期: 2017年08月14日 內容資訊: 英文 206 Pages
簡介

全球疫苗市場規模,預計2017年達492億7000萬美元,2022年達343億美元,預計以7.5%的年複合成長率 (CAGR) 擴大。市場主要的成長因素,有各種疾病的患者數多,及公民營雙方對疫苗開發的援助,對疫苗接種計劃的關注增加等。另一方面,巨額的疫苗開發費用,及產品回收的問題也可能妨礙市場成長。

本報告提供全球疫苗市場相關分析,產品概要和市場基本結構、潛力,主要的市場促進、阻礙因素,市場趨勢與今後的預測 (過去2年、今後6年份),各技術、各類型、各疾病、各投藥途徑、各終端用戶、各地區的詳細趨勢,市場競爭的狀態,今後的技術開發、市場發展的方向性,主要企業簡介等調查。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 簡介
  • 市場動態
    • 推動因素
      • 感染疾病的患病人數多
      • 疫苗接種產業愈來愈受重視
      • 對疫苗開發的政府津貼的增額
      • 對疫苗的研究開發 (R&D) 的企業投資的擴大
    • 阻礙因素
      • 疫苗開發費用高
      • 產品回收
    • 市場機會
      • 新興國家市場的急速成長預測
      • 對治療用疫苗的關注
      • 疫苗的佐劑 (助劑)的利用
    • 課題
      • 疫苗取得的困難
    • 目前的挑戰
      • 疫苗的價格設定

第6章 產業分析

  • 投資分析
  • 全球各國的法規環境
  • 主要的開發中產品
  • 新型疫苗的市場機會
    • HIV疫苗
      • 產品平台
      • 公私合營產業 (PPI)
      • 資金籌措
    • 瘧疾疫苗
    • 茲卡疫苗
    • 伊波拉疫苗

第7章 疫苗市場:各技術

  • 簡介
  • 結合型疫苗
  • 惰性化、次單元疫苗
  • 弱毒化活病毒疫苗
  • 基因改造疫苗
  • 類毒素疫苗

第8章 疫苗市場:各類型

  • 簡介
  • 單價疫苗
  • 多價疫苗

第9章 疫苗市場:各適應症

  • 簡介
  • 肺炎球菌性疾病
  • DTP (三種混合疫苗)
  • 流感
  • 人類乳突病毒 (HPV)
  • 腦膜炎性疾病
  • 脊髓灰質炎 (兒童麻痺)
  • 輪狀病毒
  • 肝炎
  • MMR (新三種混合疫苗)
  • 水痘
  • 登革熱
  • 其他

第10章 疫苗市場:各給藥途徑

  • 簡介
  • 肌肉內、皮下注射治療 (IM, SC)
  • 口服給藥
  • 其他

第11章 疫苗市場:各終端用戶

  • 簡介
  • 兒童
  • 成人

第12章 疫苗市場:各地區

  • 簡介
  • 北美 (美國,加拿大)
  • 歐洲 (德國,英國,法國,義大利,西班牙等)
  • 亞洲 (日本,中國,印度等)
  • 其他的國家 (RoW)

第13章 競爭環境

  • 簡介
  • 市場佔有率分析
  • 企業策略方向性:製圖
    • 企業先驅
    • 創新的企業
    • 活動的企業
    • 新企業
  • 產品系列的擴充度 (共25家公司份)
  • 產業策略的優秀性 (共25家公司份)

第14章 企業簡介

  • PFIZER, INC.
  • GLAXOSMITHKLINE PLC.
  • MERCK & CO., INC.
  • SANOFI PASTEUR SA
  • CSL LIMITED
  • EMERGENT BIOSOLUTIONS, INC.
  • JOHNSON & JOHNSON
  • MEDIMMUNE, LLC (ASTRAZENECA的子公司)
  • Astellas Pharma Inc.
  • SERUM INSTITUTE OF INDIA
  • BAVARIAN NORDIC
  • 田邊三菱製藥
  • 第一三共
  • PROTEIN SCIENCES CORPORATION
  • PANACEA BIOTEC

第15章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 3113

"Global vaccines market projected to grow at a CAGR of 7.5%"

The vaccines market is expected to reach USD 49.27 billion by 2022 from USD 34.30 billion in 2017, at a CAGR of 7.5%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development and product recalls.

"Conjugate vaccines are expected to dominate the market during the forecast period."

By technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate segment is expected to hold the largest share of the market in 2017 and is also projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government investments are the key factors driving the growth of this segment.

"Monovalent vaccines segment expected to hold the largest share of the market in 2017."

Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.

"Pneumococcal disease segment is expected to witness high growth during the forecast period"

Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share and is projected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal disease.

"Asia to witness high growth during the forecast period"

In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 36%; Tier 2 - 41%; Tier 3 - 23%.
  • By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
  • By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
  • By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.

List of companies profiled in the report:

  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Sanofi Pasteur SA
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • Johnson & Johnson
  • MedImmune, LLC
  • Astellas Pharma Inc.
  • Serum Institute of India
  • Bavarian Nordic
  • Mitsubishi Tanabe Pharma Corporation
  • Daiichi Sankyo Company, Limited
  • Protein Science Corporation
  • Panacea Biotec

Research Coverage:

The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKET COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATION
  • 1.6. MARKET STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. SECONDARY DATA
  • 2.2. PRIMARY DATA
  • 2.3. KEY INDUSTRY INSIGHTS
  • 2.4. MARKET SIZE ESTIMATION
  • 2.5. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.6. MARKET SHARE ESTIMATION
  • 2.7. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. OVERVIEW OF THE VACCINES MARKET
  • 4.2. VACCINES MARKET, BY TYPE, 2017-2022
  • 4.3. VACCINES MARKET, BY END USER, 2017 VS. 2022(USD BILLION)
  • 4.4. GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY
  • 4.5. VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017 VS. 2022(USD BILLION)
  • 4.6. GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. High prevalence of infectious diseases
      • 5.2.1.2. Rising focus on immunization programs
      • 5.2.1.3. Growing government support for vaccine development
      • 5.2.1.4. Increasing company investments into vaccine R&D
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High cost of vaccine development
      • 5.2.2.2. Product Recalls
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. High growth prospects in emerging markets
      • 5.2.3.2. Focus on therapeutic vaccines
      • 5.2.3.3. Use of adjuvants in vaccines
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Inadequate access to vaccines
    • 5.2.5. BURNING ISSUES
      • 5.2.5.1. Vaccine pricing

6. INDUSTRY INSIGHTS

  • 6.1. INVESTMENT ANALYSIS
  • 6.2. REGULATORY LANDSCAPE
    • 6.2.1. NORTH AMERICA
    • 6.2.2. EUROPE
    • 6.2.3. ASIA
    • 6.2.4. ROW
  • 6.3. KEY PIPELINE PRODUCTS
  • 6.4. NEW VACCINE OPPORTUNITIES
    • 6.4.1. HIV
      • 6.4.1.1. HIV vaccine: Product pipeline
      • 6.4.1.2. HIV vaccine: Public-private initiatives
      • 6.4.1.3. HIV vaccine: Funding
    • 6.4.2. MALARIA
      • 6.4.2.1. Malaria vaccine: Product pipeline
      • 6.4.2.2. Malaria vaccine: Public-private initiatives
    • 6.4.3. ZIKA
      • 6.4.3.1. Zika vaccine: Product pipeline
      • 6.4.3.2. Zika vaccine: Public-private initiatives
      • 6.4.3.3. Zika vaccine: Funding
    • 6.4.4. EBOLA
      • 6.4.4.1. Ebola vaccine: Product pipeline
      • 6.4.4.2. Ebola vaccine: Public-private initiatives
      • 6.4.4.3. Ebola vaccine: Funding

7. VACCINES MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. CONJUGATE VACCINES
  • 7.3. INACTIVATED AND SUBUNIT VACCINES
  • 7.4. LIVE ATTENUATED VACCINES
  • 7.5. RECOMBINANT VACCINES
  • 7.6. TOXOID VACCINES

8. VACCINES MARKET, BY TYPE

  • 8.1. INTRODUCTION
  • 8.2. MONOVALENT VACCINES
  • 8.3. MULTIVALENT VACCINES

9. VACCINES MARKET, BY DISEASE INDICATION

  • 9.1. INTRODUCTION
  • 9.2. PNEUMOCOCCAL DISEASE
  • 9.3. DTP
  • 9.4. INFLUENZA
  • 9.5. HUMAN PAPILLOMA VIRUS
  • 9.6. MENINGOCOCCAL DISEASE
  • 9.7. POLIO
  • 9.8. ROTAVIRUS
  • 9.9. HEPATITIS
  • 9.10. MMR
  • 9.11. VARICELLA
  • 9.12. DENGUE
  • 9.13. OTHER DISEASE INDICATIONS

10. VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 10.1. INTRODUCTION
  • 10.2. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
  • 10.3. ORAL ADMINISTRATION
  • 10.4. OTHER ROUTES OF ADMINISTRATION

11. VACCINES MARKET, BY END USER

  • 11.1. INTRODUCTION
  • 11.2. PEDIATRICS
  • 11.3. ADULTS

12. VACCINES MARKET, BY REGION

  • 12.1. INTRODUCTION
  • 12.2. NORTH AMERICA
    • 12.2.1. U.S.
    • 12.2.2. CANADA
  • 12.3. EUROPE
    • 12.3.1. GERMANY
    • 12.3.2. U.K.
    • 12.3.3. FRANCE
    • 12.3.4. ITALY
    • 12.3.5. SPAIN
    • 12.3.6. REST OF EUROPE (ROE)
  • 12.4. ASIA
    • 12.4.1. JAPAN
    • 12.4.2. CHINA
    • 12.4.3. INDIA
    • 12.4.4. REST OF ASIA (ROA)
  • 12.5. REST OF THE WORLD (ROW)

13. COMPETITIVE LANDSCAPE

  • 13.1. INTRODUCTION
  • 13.2. MARKET SHARE ANALYSIS
  • 13.3. COMPETITIVE LEADERSHIP MAPPING
    • 13.3.1. VISIONARY LEADERS
    • 13.3.2. INNOVATORS
    • 13.3.3. DYNAMIC DIFFERENTIATORS
    • 13.3.4. EMERGING COMPANIES
  • 13.4. STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS)
  • 13.5. BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS)

Top 25 companies analyzed for this studies are - Pfizer, Inc., GlaxoSmithKline plc., Merck & Co., Inc., Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, MedImmune, LLC, Astellas Pharma Inc., Serum Institute of India, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Protein Science Corporation, Daiichi Sankyo Company, Limited, Abbott Laboratories, Panacea Biotec, PaxVax, Inc., Zydus Cadila, Green Cross Corporation, Valneva SE, Indian Immunologicals Limited, Incepta Vaccine Ltd., Sinovac Biotech Ltd., VBI Vaccines Inc., PT Bio Farma (Persero)

14. COMPANY PROFILES (Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*

  • 14.1. PFIZER, INC.
  • 14.2. GLAXOSMITHKLINE PLC.
  • 14.3. MERCK & CO., INC.
  • 14.4. SANOFI PASTEUR SA
  • 14.5. CSL LIMITED
  • 14.6. EMERGENT BIOSOLUTIONS, INC.
  • 14.7. JOHNSON & JOHNSON
  • 14.8. MEDIMMUNE, LLC (A SUBSIDIARY OF ASTRAZENECA)
  • 14.9. ASTELLAS PHARMA, INC.
  • 14.10. SERUM INSTITUTE OF INDIA
  • 14.11. BAVARIAN NORDIC
  • 14.12. MITSUBISHI TANABE PHARMA CORPORATION
  • 14.13. DAIICHI SANKYO COMPANY, LIMITED
  • 14.14. PROTEIN SCIENCES CORPORATION
  • 14.15. PANACEA BIOTEC

*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.

15. APPENDIX

  • 15.1. INSIGHTS OF INDUSTRY EXPERTS
  • 15.2. DISCUSSION GUIDE
  • 15.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 15.5. AVAILABLE CUSTOMIZATIONS
  • 15.6. RELATED REPORTS
  • 15.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: INCIDENCE OF DISEASES, 2015
  • TABLE 2: NIH FUNDING FOR VACCINE RESEARCH, 2012-2017(USD MILLION)
  • TABLE 3: IMMUNIZATION COVERAGE, BY DISEASE, 2014VS 2015
  • TABLE 4: REGULATORY AUTHORITIES IN EUROPE
  • TABLE 5: REGULATORY AUTHORITIES IN ASIA
  • TABLE 6: KEY PIPELINE VACCINES
  • TABLE 7: ESTIMATED INVESTMENT IN HIV VACCINES, BY INVESTOR (2015-2016)
  • TABLE 8: EBOLA PROJECTS FUNDED BY EUROPEAN COMMISSION (2014-2020)
  • TABLE 9: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 10: COST OF MENINGOCOCCAL CONJUGATE VACCINES
  • TABLE 11: CONJUGATE VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 12: EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES
  • TABLE 13: INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: LIVE ATTENUATED VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 15: EXAMPLES OF RECOMBINANT VACCINES
  • TABLE 16: RECOMBINANT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 17: TOXOID VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 18: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 19: MONOVALENT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 20: EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET
  • TABLE 21: MULTIVALENT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 22: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
  • TABLE 23: LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET
  • TABLE 24: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 25: LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET
  • TABLE 26: VACCINES MARKET FOR DTP, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 27: LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET
  • TABLE 28: VACCINES MARKET FOR INFLUENZA, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 29: LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
  • TABLE 30: VACCINES MARKET FOR HPV, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 31: LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
  • TABLE 32: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 33: LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET
  • TABLE 34: VACCINES MARKET FOR POLIO, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 35: LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET
  • TABLE 36: VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 37: LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET
  • TABLE 38: VACCINES MARKET FOR HEPATITIS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 39: LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET
  • TABLE 40: VACCINES MARKET FOR MMR, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 41: LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET
  • TABLE 42: VACCINES MARKET FOR VARICELLA, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 43: LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS IN THE MARKET
  • TABLE 44: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 45: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 46: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 47: VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 48: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 49: VACCINES MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 50: PEDIATRIC VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 51: NORTH AMERICA: PEDIATRIC VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 52: ADULT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 53: NORTH AMERICA: ADULT VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 54: VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 55: NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 56: NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 57: NORTH AMERICA: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 58: NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
  • TABLE 59: NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 60: NORTH AMERICA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 61: U.S.: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 62: U.S.: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 63: CANADA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 64: CANADA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 65: EUROPE: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 66: EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 67: EUROPE: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 68: EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
  • TABLE 69: EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 70: EUROPE: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 71: GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 72: U.K.: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 73: FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 74: ITALY: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 75: SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 76: ROE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 77: ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 & 2014 (USD)
  • TABLE 78: ASIA: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 79: ASIA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 80: ASIA: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 81: ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
  • TABLE 82: ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 83: ASIA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
  • TABLE 84: JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 85: CHINA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 86: INDIA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 87: ROA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 88: ROW: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 89: ROW: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 90: ROW: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
  • TABLE 91: ROW: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
  • TABLE 92: ROW: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: VACCINES MARKET SEGMENTATION
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 4: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 5: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 6: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 7: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 8: DATA TRIANGULATION METHODOLOGY
  • FIGURE 9: VACCINES MARKET, BY TECHNOLOGY, 2017-2022
  • FIGURE 10: VACCINES MARKET, BY TYPE, 2017 VS. 2022 (USD BILLION)
  • FIGURE 11: VACCINES MARKET, BY DISEASE INDICATION, 2017 VS. 2022 (USD BILLION)
  • FIGURE 12: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2017 VS. 2022 (USD BILLION)
  • FIGURE 13: VACCINES MARKET, BY END USER, 2017 VS. 2022 (USD BILLION)
  • FIGURE 14: GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET
  • FIGURE 15: HIGH PREVALENCE OF DISEASES AND RISING GOVERNMENT & NONGOVERNMENT FUNDING FOR VACCINE DEVELOPMENT-PRIMARY GROWTH DRIVERS FOR THE GLOBAL VACCINES MARKET
  • FIGURE 16: MONOVALENT VACCINES TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 17: PEDIATRICS SEGMENT WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2022
  • FIGURE 18: CONJUGATE VACCINES TO ACCOUNT FOR THE LARGEST SHARE OF THE VACCINES MARKET IN 2017
  • FIGURE 19: INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
  • FIGURE 20: U.S. TO DOMINATE THE VACCINES MARKET IN 2017
  • FIGURE 21: VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22: MAJOR INVESTORS IN THE GLOBAL VACCINES MARKET
  • FIGURE 23: VACCINE FUNDING, BY INVESTOR, 2014
  • FIGURE 24: GAVI VACCINE FUNDING, BY TYPE OF INVESTOR, 2014
  • FIGURE 25: GAVI FORECAST VACCINE EXPENDITURE, BY DISEASE, 2016-2020
  • FIGURE 26: REGULATORY APPROVAL PROCESS FOR VACCINES
  • FIGURE 27: R&D FUNDING FOR HIV PREVENTIVE VACCINES, BY INVESTOR, 2014
  • FIGURE 28: CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINE TECHNOLOGIES MARKET DURING THE FORECAST PERIOD
  • FIGURE 29: MONOVALENT VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET IN 2017
  • FIGURE 30: PNEUMOCOCCAL DISEASE SEGMENT WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN 2022
  • FIGURE 31: GLOBAL VACCINES MARKET FOR DENGUE, 2015-2022 (USD MILLION)
  • FIGURE 32: INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT WILL CONTINUE TO DOMINATE THE GLOBAL VACCINES MARKET IN 2022
  • FIGURE 33: PEDIATRICS END-USER SEGMENT TO DOMINATE THE GLOBAL VACCINES MARKET IN 2017
  • FIGURE 34: NORTH AMERICA: VACCINES MARKET SNAPSHOT, 2017
  • FIGURE 35: EUROPE: VACCINES MARKET SNAPSHOT, 2017
  • FIGURE 36: ASIA: VACCINES MARKET SNAPSHOT, 2017
  • FIGURE 37: ROW: VACCINES MARKET SNAPSHOT, 2017
  • FIGURE 38: VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2016
  • FIGURE 39: VACCINES MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2017
  • FIGURE 40: PFIZER, INC.: COMPANY SNAPSHOT
  • FIGURE 41: GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • FIGURE 42: MERCK & CO., INC.: COMPANY SNAPSHOT
  • FIGURE 43: SANOFI PASTEUR SA: COMPANY SNAPSHOT
  • FIGURE 44: CSL LIMITED: COMPANY SNAPSHOT
  • FIGURE 45: EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT
  • FIGURE 46: JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 47: ASTRAZENECA: COMPANY SNAPSHOT
  • FIGURE 48: ASTELLAS PHARMA, INC.: COMPANY SNAPSHOT
  • FIGURE 49: BAVARIAN NORDIC: COMPANY SNAPSHOT
  • FIGURE 50: MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT
  • FIGURE 51: DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT
  • FIGURE 52: PANACEA BIOTEC: COMPANY SNAPSHOT (2016)
Back to Top